Hebei ups biopharma bragging rights

Attracted by the innovation ecosystem and supportive industrial policies, a biopharmaceutical scientist from the United States came to Shijiazhuang, capital of North China's Hebei province, to launch a joint venture.

Gai Dahai, chairman of Shijiazhuang NeoGen Biotechnology Co, settled down in the city's Central Innovation Zone — Shijiazhuang International Biomedical Industry Park — in March.

NeoGen's main undertaking is developing an immunotherapy drug for cervical cancer treatment.